, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med. 2010 May. 38(5):1284-90. [QxMD MEDLINE Link]. 15. Suzuki S, Ito O, Sayama T, Goto K. Intra-arterial colforsindaropate for the treatment of cerebral vasospasm after aneurysmal
, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med. 2010 May. 38(5):1284-90. [QxMD MEDLINE Link]. 15. Suzuki S, Ito O, Sayama T, Goto K. Intra-arterial colforsindaropate for the treatment of cerebral vasospasm after aneurysmal
, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med. 2010 May. 38(5):1284-90. [QxMD MEDLINE Link]. 15. Suzuki S, Ito O, Sayama T, Goto K. Intra-arterial colforsindaropate for the treatment of cerebral vasospasm after aneurysmal
, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2010 Mar. 112(3):681-8. [QxMD MEDLINE Link]. 47. Zhang S, Wang L, Liu M, Wu B. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2010 Feb 17. CD006778. [QxMD MEDLINE Link]. 48. Suzuki S, Ito O, Sayama T, Goto K. Intra-arterial colforsindaropate
, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med. 2010 May. 38(5):1284-90. [QxMD MEDLINE Link]. 15. Suzuki S, Ito O, Sayama T, Goto K. Intra-arterial colforsindaropate for the treatment of cerebral vasospasm after aneurysmal
, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2010 Mar. 112(3):681-8. [QxMD MEDLINE Link]. 47. Zhang S, Wang L, Liu M, Wu B. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2010 Feb 17. CD006778. [QxMD MEDLINE Link]. 48. Suzuki S, Ito O, Sayama T, Goto K. Intra-arterial colforsindaropate
L, Liu M, Wu B. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2010 Feb 17. CD006778. [QxMD MEDLINE Link]. 48. Suzuki S, Ito O, Sayama T, Goto K. Intra-arterial colforsindaropate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neuroradiology. 2010 Sep. 52(9):837-45. [QxMD MEDLINE Link]. 49. Hughes PD, Becker
Both milrinone and colforsindaropate attenuate the sustained pial arteriolar constriction seen after unclamping of an abdominal aortic cross-clamp in rabbits. We previously reported that unclamping of an abdominal aortic cross-clamp causes initial dilation of pial arteries followed by sustained constriction. Both milrinone and colforsindaropate have a vasodilator action, and both have been used in such critical conditions as abdominal aortic aneurysmectomy. We measured cerebral pial arteriolar diameters using a rabbit closed cranial window preparation before (baseline) and 15 min after the start of an IV infusion of 0.9% saline (control group), milrinone, or colforsindaropate (0.05 and 0.5 microg . /kg(-1) . min(-1)) (pre-clamp), just after aortic clamping, 20 min after clamping, and at 0 to 60 min
The effect of inhaled colforsindaropate on contractility of fatigued diaphragm in dogs. We studied the effect of inhaled colforsindaropate, a water-soluble forskolin derivative, on the contractility of fatigued diaphragm in dogs. Animals were divided into 3 groups of 8. In each group, diaphragmatic fatigue was induced by intermittent supramaximal bilateral electrophrenic stimulation at a frequency of 20-Hz stimulation applied for 30 min. Immediately after the end of the fatigue-producing period, Group 1 received inhaled vehicle, Group 2 received inhaled colforsindaropate 0.1 mg/mL, and Group 3 received inhaled colforsindaropate 0.2 mg/mL. We assessed diaphragmatic contractility by transdiaphragmatic pressure (Pdi). After fatigue was produced, in each group, Pdi at low-frequency (20-Hz
Effect of prophylactic bronchodilator treatment with intravenous colforsindaropate, a water-soluble forskolin derivative, on airway resistance after tracheal intubation. After induction of anesthesia, lung resistance increases. The authors hypothesized that prophylactic bronchodilator treatment with intravenous colforsindaropate, a water-soluble forskolin derivative, before tracheal intubation would result in decreased lung resistance and increased lung compliance after tracheal intubation when compared with placebo medication. Forty-six adult patients were randomized to placebo or colforsindaropate treatment. Patients in the control group received normal saline; patients in the colforsin group received 0.75 microg. kg-1 x min-1 colforsindaropate intravenously until the study ended
[Colforsindaropate does not affect the cerebral blood-flow in cardiac surgery patients under cardiopulmonary bypass]. Cerebral blood flow partly plays a pivotal role in cerebral complications among cardiac surgery patients. We evaluated the effect of colforsindaropate (colforsin) on cerebral blood flow in cardiac surgery patients under cardiopulmonary bypass (CPB) by transcranial Doppler
Influence of colforsindaropate hydrochloride on internal mammary artery grafts. The effect of colforsindaropate hydrochloride (colforsin), a water-soluble forskolin derivative, on blood flow in internal mammary artery (IMA) grafts was evaluated in a prospective randomized study of 26 patients undergoing coronary artery bypass grafting. Patients were randomized to receive either colforsin inversely with concurrent systemic vascular resistance (r=-0.61, p=0.001). Intraoperative administration of colforsindaropate hydrochloride caused potent vasodilation, resulting in an increase in IMA blood flow. The results indicate that the regimen can be used perioperatively in patients undergoing coronary artery bypass grafting.
Intravenous colforsindaropate, a water-soluble forskolin derivative, prevents thiamylal-fentanyl-induced bronchoconstriction in humans. Forskolin, a direct activator of adenylate cyclase, can relax airway smooth muscle, similar to other agents that increase intracellular cyclic adenine monophosphate. However, the potential usefulness of forskolin in treating bronchospasm is limited by its poor water solubility. Colforsindaropate is a novel and potent water-soluble forskolin derivative. No clinical data have been published on the bronchorelaxant effects of this drug. The aim of this study was to investigate whether intravenous colforsindaropate prevents thiamylal-fentanyl-induced bronchoconstriction. Double-blind, prospective, placebo-controlled randomized study. University teaching
[Effects of colforsindaropate hydrochloride in patients undergoing coronary artery bypass surgery]. The effects of Adehl, colforsindaropate hydrochloride, on hemodynamics were studied in patients undergoing cardiac surgery. Twenty-six patients who underwent coronary artery bypass grafting were divided into two groups according to the intraoperative administration of Adehl. The control group (n
Antiinflammatory effects of colforsindaropate hydrochloride, a novel water-soluble forskolin derivative. To evaluate the effects of colforsindaropate hydrochloride (colforsin), a water-soluble forskolin derivative, on hemodynamics and systemic inflammatory response after cardiopulmonary bypass, we conducted a prospective randomized study. Twenty-nine patients undergoing coronary artery bypass ) with the respiratory index after cardiopulmonary bypass. Intraoperative administration of colforsindaropate hydrochloride had potent inotropic and vasodilatory activity and attenuated cytokine production and respiratory dysfunction after cardiopulmonary bypass. The results indicate that the technique can be a novel therapeutic strategy for the systemic inflammatory response associated with cardiopulmonary bypass.